此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis

2017年5月17日 更新者:Roswell Park Cancer Institute

A Pilot Study to Investigate the Use of Topical Levulan® With Vbeam® Laser for the Treatment of Actinic Keratoses

RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, abnormal cells are killed. Photodynamic therapy using topical aminolevulinic acid may be effective against actinic keratosis.

PURPOSE: This randomized clinical trial is studying how well different photodynamic therapy regimens using topical aminolevulinic acid work in treating patients with actinic keratosis.

研究概览

详细说明

OBJECTIVES:

Primary

  • To determine, using fluorescence measurements, the protoporphyrin IX (PpIX) accumulation in thin actinic keratoses (AK) and actinically damaged skin on the face, scalp, and upper torso (stratum 1) and the PpIX accumulation in thick AK and actinically damaged skin on the arms and legs (stratum 2) as a function of skin preparation, aminolevulinic acid (ALA) application time, and body site.
  • To determine the extent that the PpIX is photobleached by the treatment light.

Secondary

  • To assess the effects of different treatment conditions on acute reactions of AK and sun damaged skin to ALA-photodynamic therapy (PDT) occurring 24-48 hours after PDT.
  • To assess the effects of different treatment conditions on the efficacy of ALA-PDT.
  • To examine the histological response to ALA-PDT.
  • To determine, using fluorescence measurements, the PpIX accumulation in incidental thick AK that may occur in stratum 1, and the PpIX accumulation in incidental thin AK that may occur in stratum 2 as a function of skin preparation, ALA application time and body site.
  • To determine the extent that the PpIX in these incidental lesions is photobleached by treatment light.

OUTLINE: The randomization is a two-step restricted block process for application time and skin preparation, followed by randomization for light dose (1 vs 2 pulses) within the anatomic site. Within each stratum (stratum 1 or 2), lesions in each separate anatomic area (face and neck, scalp, upper torso; arms, legs) are randomized to receive 1 of 3 pretreatment skin preparation before receiving topical aminolevulinic acid (ALA): pretreatment with acetone, gentle abrading, or no pretreatment. Patients are randomized to receive ALA at different times before the photodynamic therapy (PDT).

  • Arm I: Patients receive topical ALA 2 hours before PDT.
  • Arm II: Patients receive topical ALA 4 hours before PDT.
  • Arm III: Patients receive topical ALA 24 hours before PDT. Each anatomic area is divided into subunits (e.g., right and left arm, right and left side of the face). The subunits are randomized to receive 1 or 2 pulses of the laser treatment.
  • Arm IV: 1 Vbeam laser pulse (photodynamic therapy) is applied to the subunit.
  • Arm V: 2 Vbeam laser pulses (photodynamic therapy) are applied to the subunit. Patients may receive up to 3 treatments (including pretreatment, ALA, and PDT) at least 1 month apart. Patients with progressive lesions or lesions that have not responded after 3 treatments may receive diagnostic biopsy to check for invasive squamous cell carcinoma and referred to treatment off study.

Patients undergo biopsies at baseline, before and after ALA application prior to light treatment, and up to 24 hours after light treatment to analyze cytokines and genes specific to actinic keratoses.

研究类型

介入性

注册 (实际的)

12

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • New York
      • Buffalo、New York、美国、14263-0001
        • Roswell Park Cancer Institute

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 120年 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

DISEASE CHARACTERISTICS:

  • Actinic keratosis lesion located in any of the following body sites:

    • Stratum 1*: face and neck, scalp, or upper torso

      • At least 1 clinically evident thin actinic keratosis on each side of the midline of any of the above areas
    • Stratum 2*: arms or legs

      • At least 1 clinically evident thick actinic keratosis on each arm or leg NOTE: *One patient may be in one or both strata depending on the location of the lesion(s)
  • Lesions to be treated on this protocol must not have been previously treated by other modalities for at least 2 months prior to study entry

PATIENT CHARACTERISTICS:

  • No porphyria or known hypersensitivity to porphyrins
  • No known photosensitivity disease
  • No known sensitivity to any components of aminolevulinic acid topical solution
  • Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

  • Other concurrent topical therapies at lesion sites other than those used in this protocol are allowed
  • No other concurrent photosensitizer drugs

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm 1 - ALA
Patients receive topical ALA topical (aminolevulinic acid) 2 hours before PDT.
实验性的:Arm 2
Patients receive topical ALA topical (aminolevulinic acid) 4 hours before PDT
实验性的:Arm 3
Patients receive topical ALA (aminolevulinic acid) 24 hours before PDT. Each anatomic area is divided into subunits (e.g., right and left arm, right and left side of the face). The subunits are randomized to receive 1 or 2 pulses of the laser treatment
实验性的:Arm 4
Vbeam laser pulse (photodynamic therapy) is applied to the subunit
实验性的:Arm 5
Vbeam laser pulses (photodynamic therapy) are applied to the subunit. Patients may receive up to 3 treatments (including pretreatment, ALA, and PDT) at least 1 month apart

研究衡量的是什么?

主要结果指标

结果测量
Protoporphyrin IX (PpIX) Accumulation as a Function of Skin Preparation, Aminolevulinic Acid Application Time, and Body Site
Extent That the PpIX is Photobleached by the Treatment Light

次要结果测量

结果测量
Effects of Different Treatment Conditions on Acute Reactions of Actinic Keratoses (AK) and Sun Damaged Skin Occurring 24-48 Hours After Photodynamic Therapy
Effects of Different Treatment Conditions on Efficacy
Histological Response
PpIX Accumulation in Incidental AK as a Function of Skin Preparation, Aminolevulinic Acid Application Time, and Body Site
Extent That the PpIX is Photobleached by the Treatment Light in Incidental Lesions

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Nathalie Zeitouni, MD,、Roswell Park Cancer Institute

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2005年5月1日

初级完成 (实际的)

2009年1月1日

研究完成 (实际的)

2009年5月1日

研究注册日期

首次提交

2007年8月31日

首先提交符合 QC 标准的

2007年8月31日

首次发布 (估计)

2007年9月3日

研究记录更新

最后更新发布 (实际的)

2017年6月14日

上次提交的符合 QC 标准的更新

2017年5月17日

最后验证

2017年5月1日

更多信息

与本研究相关的术语

关键字

其他研究编号

  • I 28204
  • RPCI-I-28204

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

激光疗法的临床试验

3
订阅